| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | XAGE1 |
| Uniprot No | Q9HD64 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-69 aa |
| 活性数据 | MESPKKKNQQLKVGILHLGSRQKKIRIQLRSQVLGREMRDMEGDLQELHQSNTGDKSGFGFRRQGEDNT |
| 分子量 | 34.4 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3条关于重组人XAGE1蛋白的参考文献，简要整理如下：
1. **文献名称**：**"XAGE1 Expression in Non-Small Cell Lung Cancer and Antibody Response in Patients"**
**作者**：Smith A, et al.
**摘要**：研究利用重组XAGE1蛋白检测非小细胞肺癌(NSCLC)患者血清中的特异性抗体，发现XAGE1抗体水平升高与肿瘤进展和不良预后显著相关，提示其作为诊断生物标志物的潜力。
2. **文献名称**：**"Development of Monoclonal Antibodies Against Recombinant XAGE1 Protein for Cancer Immunodiagnosis"**
**作者**：Chen L, et al.
**摘要**：通过重组XAGE1蛋白免疫小鼠，成功制备高特异性单克隆抗体，并验证其在肿瘤组织免疫组化(IHC)中的应用，为XAGE1相关癌症(如前列腺癌)的诊断提供新工具。
3. **文献名称**：**"XAGE1 Promotes Tumor Metastasis via EGFR Signaling and Induces Immune Response in Lung Adenocarcinoma"**
**作者**：Wang Y, et al.
**摘要**：利用重组XAGE1蛋白进行功能实验，揭示其通过激活EGFR通路增强肺癌细胞侵袭能力，同时发现患者体内XAGE1特异性T细胞反应，提示其双面角色(促癌与免疫激活)。
4. **文献名称**：**"Autoantibody Signature against XAGE1 Protein in Breast Cancer Screening"**
**作者**：Lee K, et al.
**摘要**：通过ELISA检测乳腺癌患者血清中抗重组XAGE1蛋白的自身抗体，发现其敏感性与早期肿瘤相关，或可辅助现有筛查手段提高诊断准确性。
(注：以上文献为模拟示例，实际文献需检索PubMed等数据库获取。)
XAGE1 (X antigen family member 1), also known as G antigen family D member 2A (GAGED2a), is a cancer-testis antigen predominantly expressed in normal testicular germ cells but frequently overexpressed in various malignancies. It belongs to the GAGE/XAGE family, characterized by chromosome X-localized genes encoding proteins with conserved structural motifs. XAGE1 isoforms (e.g., XAGE-1a, XAGE-1b, XAGE-1d) arise from alternative splicing, with XAGE-1b being the most studied due to its association with cancer progression.
The recombinant XAGE1 protein is typically produced using expression systems like *E. coli* or mammalian cells, enabling studies on its biological roles. Structurally, it contains a conserved N-terminal XAGE domain (∼90 amino acids) linked to a C-terminal coiled-coil region, suggesting roles in protein-protein interactions. Its overexpression in cancers, including lung adenocarcinoma, prostate cancer, and Ewing’s sarcoma, correlates with tumor aggressiveness and immune evasion. As a tumor-associated antigen, XAGE1 is investigated for immunotherapy applications, with studies highlighting its potential to elicit cytotoxic T-cell responses.
Research also links XAGE1 to immune regulation and metastasis. For example, in lung adenocarcinoma, it promotes epithelial-mesenchymal transition (EMT) and upregulates matrix metalloproteinases (MMPs). Despite its oncogenic role, XAGE1’s extracellular interactions with proteins like RAGE (receptor for advanced glycation end-products) suggest dual contextual functions in cell signaling. Its restricted normal tissue expression and immunogenicity make recombinant XAGE1 a candidate for diagnostic biomarkers and vaccine development, though clinical validation remains ongoing.
×
